Hematologic Malignancy
Conditions
Keywords
Mucositis, Low level laser therapy, Autograft, Allograft
Brief summary
The LLLT has an anti-inflammatory, analgesic effect and accelerates the healing of ulcerated lesions. There are little data in the literature showing its efficacy in prevention of mucositis in cohorts of patients with hematopoietic stem cells transplantation. The main objective of this study is to assess the efficacy of a prophylactic low level laser therapy performed by nurses on the severity of oral mucositis during HSCT.
Detailed description
The main end point for efficacy is the reduction of severe mucositis (grade 3 or more). The secondary efficacy endpoints are the reduction of mucositis, whatever the grade, the reduction of time with mucositis, the time to onset of mucositis symptoms, the reduction of pain intensity and evaluation of quality of life.The secondary endpoints for safety are severe adverse events and potential toxicity. Patients will be allocated at inclusion with a 1/1 ratio either to laser-on or laser-off groups. In the laser group, patients will undergo laser therapy performed by nurses, which will consist of irradiation of the whole oral cavity during 2 minutes with 250mW power. In the laser-off group, laser therapy will be carried out with equipment off during the same time, and still performed by nurses. Protective eye shields will be used to avoid detrimental effects on eyes and to keep the subjects blind.
Interventions
DEVICELaser treatment
Patients randomized to the experimental arm receive in addition to mouthwash, preventive treatment of mucositis by LLLT performed by nurses consisting of daily scanning the entire oral cavity for 2 minutes with a power of 250 mW, starting with conditioning and ongoing until the onset of mucositis of grade 1. If the mucositis is localised, preventive laser will be kept on the healthy zones, and curative laser will be performed on painful zone. If the mucositis is general (more than 1 site), preventive laser is stopped for curative laser only.
DEVICEPlacebo
Patients randomized to the Placebo arm receive in addition to mouthwash fictive laser treatment performed by nurses until the onset of mucositis of grade 1. If the mucositis is localised, fictive laser will be kept on the healthy zones, and curative laser will be performed on painful zone. If the mucositis is general (more than 1 site), fictive laser is stopped for curative laser only.
Sponsors
Hospices Civils de Lyon
Centre Leon Berard
Société Biophoton
Institut de Cancérologie de la Loire
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Caregiver, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patient undergoing autologous or allogeneic HSC (Hematopoietic Stem Cell) transplantation with myeloablative conditioning * Patient affiliated to a social security * Signed inform consent
Exclusion criteria
* Patient undergoing HSCT (Hematopoietic Stem Cell Transplantation) with reduced intensity conditioning Slavin (FB2) or Seattle (F-2 Gy TBI) * Protected major patient * Pregnant woman * Patient with pacemaker * Epileptic Patient
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| prevalence of grade 3 mucositis and more | 30 days | prevalence of grade 3 and more mucositis following the classification proposed by WHO (world health organization) |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| duration of mucositis | 30 days | The duration of mucositis will be reported at day 30 post graft for all patients. |
| time of onset of mucositis | 30 days | time of onset of mucositis will be assessed by measuring the interval between the beginning of packaging and the first day of mucositis has been assessed at a grade 1 |
| number of all grades of mucositis | 30 days | The number of all grades of mucositis will be reported at day 30 post graft for all patients. |
| Quality of life | 30 days | Quality of life will be reported for each patient during their participation: 30 days post graft maximum. |
| Safety | 30 days | serious adverse events will be reported for each patient during their participation: 30 days post graft maximum. |
| Pain | 30 days | Pain will be reported for each patient during their participation: 30 days post graft maximum. |
Countries
France
Outcome results
None listed